Press release
Chronic Pain Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and according to DelveInsight
Unlock key insights into the Chronic Pain Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chronic Pain Market Size [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Pain Market Report
* In November 2024:- Evon Medics LLC- The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain [CBOT-Pain (or CBOT-P)] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) to determine its short- and long-term effectiveness on Pain, Negative Affect (NA), Cognition and Cortical Brain Structure (PACS), long-term safety, and indications.
* In November 2024:- Hanmi Pharmaceutical Company Limited- A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 as compared to RLD2401 in Chronic Low-Back Pain Patients.
* The total 7MM Chronic Pain Prevalent Cases in 2023 US accounted the highest cases.
* Among the EU4 and the UK, the highest number of Chronic Pain prevalent cases were observed in the UK ~ 30%.
* Prevalence of chronic pain increased with age and was higher among those in age group between 45-64 years.
* Approximately 70% of chronic pain cases in the United States in 2023 fall within the category of moderate to severe severity-specific cases.
* The Chronic Pain Companies such as AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH , and others.
* Promising Chronic Pain Therapies such as Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide , and others.
Stay ahead in the competitive landscape of the Chronic Pain Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chronic Pain Treatment Market Size [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pain Epidemiology Segmentation in the 7MM
* Total Chronic Pain Prevalent Cases
* Total Chronic Pain Diagnosed Cases
* Chronic Pain Severity-specific Cases
* Chronic Pain Age-specific Cases
* Chronic Pain Cause-specific Cases
Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Prevalence [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pain Marketed Drugs
* JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Improvement of symptoms of osteoarthritis (knee joint and hip joint) is expected by administering JOYCLU into the joint cavity once every 4 weeks. JOYCLU is the first joint function improvement agent in Japan to treat osteoarthritis of the hip joint.
* ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an intra-articular injection to manage osteoarthritis pain in the knee. ZILRETTA is Flexion's novel, proprietary, sustained-release formulation composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix that extends residence time in the joint for the treatment of mild-to-moderate OA of the knee. ZILRETTA received approval from the FDA on October 2017.
Chronic Pain Emerging Drugs
* ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals.
Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucuronoxylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). GAGs are complex carbohydrates that play a regulatory role in the body through interacting with proteins involved with inflammation. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties, as well as its mild anti-thrombotic activity.
* TNX-102 SL: Tonix Pharmaceuticals
TNX-102 SL, a sublingual tablet with 2.8 mg of cyclobenzaprine HCl, is taken nightly to treat fibromyalgia. Its rapid absorption and reduced production of a long-lasting active metabolite enhance its effectiveness. This patented formulation optimizes cyclobenzaprine delivery to improve sleep quality and minimize residual effects. TNX-102 SL, a centrally-acting analgesic, eases pain by enhancing sleep. It's currently in mid-Phase III development for fibromyalgia management.
Discover the future of Chronic Pain Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chronic Pain Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pain Drugs Market
Currently, several types of medications are being used in the management of chronic pain, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic treatments for chronic pain can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for the treatment of chronic pain such as EMGALITY (galcanezumab-gnlm), AIMOVIG (erenumab), and AJOVY (fremanezumab), among others.
Chronic Pain Market Outlook
Key Chronic Pain Companies such as Paradigm Biopharmaceuticals, Centrexion Therapeutics, Tonix Pharmaceuticals, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Chronic Pain. According to DelveInsight's analysis, the Chronic Pain Market Growth is expected to be mainly driven by increasing Chronic Pain Prevalence, rise in awareness and access to treatment, alternative options (such as a novel therapeutic agent) to addictive opioids, holistic approach, efforts by the organization and upsurge in the geriatric population.
Explore the dynamics of the Chronic Pain Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chronic Pain Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Pain Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Chronic Pain Companies- AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
* Chronic Pain Therapies- Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.
* Chronic Pain Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Chronic Pain Market Overview at a Glance
4 Executive Summary of Chronic Pain
5 Key events
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Marketed Products
10 Emerging Therapies
11 Chronic Pain: The Seven Major Markets Analysis
12 SWOT Analysis
13 Unmet Needs
14 KOL Views
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pain-therapeutics-market-size-in-the-7mm-is-anticipated-to-increase-by-2034-and-according-to-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/lactose-intolerance-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Pain Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and according to DelveInsight here
News-ID: 3828577 • Views: …
More Releases from ABNewswire
Cancer Caregiving with Heart and Humor: Award-winning Novelist and Emmy-Nominate …
Inspired by Maren Higbee's real-life cancer journey with her husband, A Cancer Patient's Wife is a powerful reminder that amidst life's hardest battles, it's humor, love, and the people who stand by you that make all the difference, even when healing feels impossible.
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXfyLDlU9v3W9al25ooalPN8SyuomdUiLn7axP9UU0T-arFp-hwSArKlbBJDwvCQcghgvQu7v1voGabqVxu8_ErJAVFr-MCb88zcj3E160YIWCm5RGI29qr-onnxxgD4KfD6FSfHSA?key=haqQSW-l7T0DKkm-GQwZYQ01
Maren Higbee is an Emmy-nominated producer, award-winning novelist, and storyteller who's spent her career crafting memorable narratives. Her work spans from hit TV shows like The Deadliest…
Idiopathic Membranous Nephropathy Market, 2034 | Bristol Myers Squibb Company, M …
The Idiopathic Membranous Nephropathy market growth is driven by factors like increase in the prevalence of Idiopathic Membranous Nephropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Idiopathic Membranous Nephropathy market report [https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Idiopathic Membranous Nephropathy market size, share, Idiopathic Membranous Nephropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market…
Monjur and MSPAlliance Announce Strategic Partnership to Improve Cybersecurity a …
Southlake, Texas - February 18, 2025 - Monjur, renowned for its innovative contract solutions for managed service providers (MSPs), has joined forces with MSPAlliance, the world's largest international cloud and managed services association. This strategic partnership, founded on the extensive expertise of both Monjur and MSPAlliance, will see the two entities promote and market each other's solutions. They will also integrate Monjur's expertise in customer contracting with the MSPAlliance Cyber…
Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Thera …
The Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Epidermolysis Bullosa market report [https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=blog&utm_medium=promotion&utm_campaign=kpr] also offers comprehensive insights into the Epidermolysis Bullosa market size, share, Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and…
More Releases for Pain
Global Pain Management Devices Market Study Analysis: Adoption Of Pain Managemen …
The fast-food market size was valued at $ billion in 2020 and is estimated to reach $ billion by 2028, growing at a CAGR of 6.3% during the forecast period. Pain is an unpleasant sensation and emotional experience caused due to actual or potential tissue damage or illness. Pain can be caused due to accidental injuries, or due to diseases like osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer,…
Flexotone Joint Pain Relief Reviews: Get Relief from Joint Pain & Arthritis
Joint pain & inflammation has come to be an instead usual problem among older consumers, as well as they are frequently entrusted to identify exactly how to deal with these problems with a topical cream or resting. Nevertheless, the makers behind Flexotone think that the reason behind this concern has every little thing to do with something that takes place within the joints. This trouble triggers unbelievable pain; however Big…
Nerve Pain Treatment: 3 Top Neuropathy Pain Relief Pills
Neuropathy affects your extremities or nerves by producing tingling, discomfort, or numbness. Diabetics frequently suffer from neuropathy. According to the American Diabetes Association, around 65 percent of people suffering from diabetes face varying degrees of nerve damage, which results in diabetic neuropathy.
Neuropathy can also occur due to different reasons, like alcoholism, trauma, or autoimmune disorders. Some people acquire neuropathy due to physical injury to their nerves, for instance. Others have…
Post-operative Pain Management Market 2018 by Pain Type - Acute Pain, Moderate P …
Post-operative Pain Management Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover Key Market Driver, market size, growth rate, opportunities, market Dynamics and Overall Analysis. And also cover the other information such as Post-operative Pain Management Market trends, Prominent players, chapter-wise Description followed by various user perceptions and Forecast till 2023.
Global Post-operative Pain Management Market - Overview
Post-operative pain management is the most important part…
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in…
Middle East Tapentadol Market by Therapeutic Application Pain Management Neuropa …
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and…
